Combined transcriptomic profiling of anti-PD-1 immunotherapy and FGFR inhibitor AZD4547 in a CT26 colorectal cancer syngeneic mouse model

BALB/c mice bearing CT26 subcutaneous tumors were randomized into four treatment groups: Rat IgG2a + PBS (control), anti-PD-1 antibody (anti-PD-1), FGFR inhibitor AZD4547 (FGFRi), and AZD4547 plus anti-PD-1 combination (FGFRi+anti-PD-1). Total RNA was extracted from tumor tissues and subjected to paired-end bulk RNA-seq on the Illumina NovaSeq 6000 platform (PE150).

Clean reads were aligned to the mouse reference genome GRCm38/mm10, and gene expression was quantified as raw counts and FPKM, followed by differential expression and enrichment analyses.